1-5 of 5
Mihaela Popa-McKiver, PhD
Close
Sort by
Journal Articles

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Katja Weisel, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo
Journal: Blood
Blood (2019) 134 (Supplement_1): 3480.
https://doi.org/10.1182/blood-2019-122232
Published: 2019
Journal Articles

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Ann Forslund, PhD, Hao Tang, Chunzhe Duan, Mihaela Popa-McKiver, PhD, James R. Berenson, MD, Michael Robbins, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1853.
https://doi.org/10.1182/blood-2019-128760
Published: 2019
Journal Articles

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Mitsuo Hori, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD PhD, Shigeki Ito, MD PhD, Junya Kuroda, MD PhD, Mihaela Popa-McKiver, PhD, Ying-Ming Jou, Suresh G. Shelat, PhD, Masafumi Miyoshi, Kenshi Suzuki, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3260.
https://doi.org/10.1182/blood-2018-99-116225
Published: 2018
Journal Articles

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Initial Data from a Phase 2, Non-Comparative Study

Sundar Jagannath, MD, Jesus G. Berdeja, MD, Robert M Rifkin, MD, Craig E. Cole, MD, Michael Alan Thompson, MD PhD, Ravi Vij, MBBS, Mihaela Popa-McKiver, PhD, Rao Saleem, Oumar Sy, PhD, William Bensinger, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1991.
https://doi.org/10.1182/blood-2018-99-112077
Published: 2018
Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Katja Weisel, MD, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Ashlee Espensen, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2288.
https://doi.org/10.1182/blood-2018-99-112080
Published: 2018